The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...